PolyPid is about to post a quarter that looks nothing like its history, and almost none of the reasons have to do with selling drugs. Wall Street expects the Israeli antibiotic developer to report earnings of $0.46 per share on revenue of about $30.0 million when it releases third-quarter results before the market opens on November 11. That compares with a loss of $0.37 per share in the same quarter last year and a loss of $0.35 last quarter, a swing that works out to expected growth of roughly 224%. The catch is that the $30 million revenue estimate lines up almost exactly with the upfront and near-term payments from the Azurity Pharmaceuticals partnership signed in July. This is a one-time windfall, not a run rate, and the more consequential event arrives about two and a half weeks later, when the FDA reaches its November 28 decision on D-PLEX100.
The Street's math rests on how PolyPid accounts for that cash. Management described $30 million as secured from the signing and the NDA-acceptance milestone, so the estimate effectively assumes the full amount lands as revenue this quarter. If any portion is deferred or recognized over time, the headline numbers could fall well short of consensus without anything going wrong in the business. Investors should look past the reported EPS and focus on the cash balance. PolyPid ended June with just $6.6 million, down from $12.9 million at the end of 2025. A September cash figure that clearly reflects the Azurity inflows would support management's claim that its runway now stretches into 2028, up from the second half of 2026 only a quarter earlier. Steady operating costs would help as well. R&D held near $6 million last quarter and the net loss narrowed to $7.8 million.
The previous call marked the moment PolyPid's long-running promises became contracts. For several quarters, management had described partner talks as advanced and then late stage. Then came Azurity, which brings more than 200 U.S. sales reps, reach into about 1,700 hospitals and an existing colorectal call point. The deal also carries more than $290 million in potential milestones, tiered royalties from the mid-teens to the mid-twenties, and a transfer price on product PolyPid manufactures. Days later the FDA accepted the NDA with no filing issues and granted priority review. This report should show whether that momentum is holding. Useful evidence would include confirmation that the European marketing application was submitted in the third quarter as planned, details on the Azurity-funded label expansion program, and signs of launch readiness on Azurity's side.
The item that matters most is the one management has flagged as a risk on every recent call: the FDA's pre-approval inspection of PolyPid's Israeli manufacturing facility. Because PolyPid makes the product and earns a transfer price on each unit, the plant is central to both the approval and the deal's economics. Any update showing the inspection is complete without significant findings would remove the last major obstacle before the decision date. Silence or vague language would leave the stock trading on a binary bet.
The market has already rewarded the summer's progress. Shares are up 18.1% since the last report, while the S&P 500 fell 2.9% over the same stretch. At $5.42, the stock sits comfortably above its 200-day moving average of $4.73 but about 7% below its post-earnings high of $5.84, so it is not testing a breakout. Sentiment has cooled, with bullish readings easing to 10.8% from 20.0% a quarter ago. That suggests traders are cautious about chasing a stock that has a regulatory verdict around the corner.
The central question is not whether PolyPid tops a consensus built on milestone revenue. It is whether management can show that the plant, the cash and the partner are ready for approval. A clean inspection update and a well-funded balance sheet would keep the story that turned last quarter intact heading into November 28.